Search clinical trials for: TD-8236

Total 180 results

Theravance Biopharma

Completed

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Asthma

United Kingdom
Theravance Biopharma

Completed

Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Asthma

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Hypertension
Theravance Biopharma

Completed

Multiple Dose Ethnobridging PK Study in Healthy Subjects

Inflammatory Bowel Diseases | IBD

United States
Theravance Biopharma

Completed

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Bowel Diseases, Inflammatory | Intestinal Disorders

United States
Boryung Biopharma Co., Ltd.

Completed

To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

Tetanus | Diphtheria

Korea, Republic of
Theravance Biopharma

Terminated

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Theravance Biopharma

Completed

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

United States
Theravance Biopharma

Completed

Phase 2 Study of TD-9855 to Treat Fibromyalgia

Fibromyalgia

United States
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Theravance Biopharma

Completed

TD-9855 Mass Balance Study

Fibromyalgia | ADHD

United States
Theravance Biopharma

Completed

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

Parkinson Disease | Orthostatic Hypotension | Neurogenic Orthostatic Hypotension | Hypotension, Orthostatic | Pure Autonomic Failure | Multiple System Atrophy (MSA) With Orthostatic Hypotension | Pure Autonomic Failure With Orthostatic Hypotension | Parkinson Disease With Orthostatic Hypotension

United States
Theravance Biopharma

Completed

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD | Attention-Deficit/Hyperactivity Disorder

United States
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

Renal Impairment

United States
Theravance Biopharma

Completed

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

Acute Lung Injury (ALI) Associated With COVID-19 | Inflammatory Lung Conditions Associated With COVID-19

United Kingdom
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Korea University Guro Hospital

Completed

Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine

Pneumococcal Infections | Tetanus | Diphtheria
Theravance Biopharma

Completed

TD-1211 IV/Oral Mass Balance Study

OIC

United States
Duke University

Completed

Lymph Drainage in Heart Failure

Heart Failure

United States
Theravance Biopharma

Terminated

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

United Kingdom
Theravance Biopharma

Completed

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Symptomatic Neurogenic Orthostatic Hypertension | nOH

United States
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-1439 in Healthy Subjects

Healthy Subjects

United States
Theravance Biopharma

Completed

TD-6450 SAD and MAD in Healthy Subjects

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Mylan Inc.
Theravance Biopharma

Completed

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Theravance Biopharma
Alfasigma S.p.A.

Completed

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study (DIGEST)

Gastroparesis
University of Sao Paulo

Completed

Real and Virtual Environments in Autism Spectrum Disorder

Autism Spectrum Disorder

Brazil
Theravance Biopharma

Completed

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-1473 for Active Ulcerative Colitis (UC)

Ulcerative Colitis, Active Severe | Ulcerative Colitis, Active Moderate

United States, Georgia, Moldova, Republic of, Romania
Theravance Biopharma

Completed

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

Healthy

United States
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Theravance Biopharma

Completed

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Constipation

United States
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Merck Sharp & Dohme LLC

Terminated

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

Atopic Dermatitis
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

Hypertension
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Estonia, Canada, France, Chile
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

Bowel Diseases, Inflammatory | Intestinal Disorder

United States
Merck Sharp & Dohme LLC
ALK-Abelló A/S

Completed

MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)

Allergic Rhinitis | Allergic Rhinoconjunctivitis
Theravance Biopharma

Completed

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Chronic Constipation

United States
Theravance Biopharma

Terminated

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)

Crohn's Disease

United States, Bulgaria, France, Georgia, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Portugal, Romania, Serbia, South Africa, Spain, Ukraine, Australia, Austria, Croatia, New Zealand, Russian Federation, United...
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

Solid Tumors, Adult

United States
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Theravance Biopharma

Completed

TD-0903 for ALI Associated With COVID-19

Acute Lung Injury (ALI) Associated With COVID-19 | Lung Inflammation Associated With COVID-19

Moldova, Republic of, United Kingdom, United States, Brazil, Finland, Romania, Ukraine
IBSS Biomed S.A.

Active, not recruiting

Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria. (Clodivac)

Tetanus | Diphtheria

Poland
Emory University
Universidad del Valle, Guatemala

Completed

Maternal Tdap Immunization in Guatemala

Pertussis | Whooping Cough

Guatemala
Mylan Inc.
Theravance Biopharma

Completed

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

COPD

New Zealand

Search clinical trials for: TD-8236

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations